From Nasdaq: 2025-02-03 07:43:00

The fourth-quarter 2024 earnings season for the Medical sector is in progress, with pharma and medical device companies reporting. Check the Zacks Earnings Calendar for updates. Several pharma giants like J&J, AbbVie, Novartis, Roche, and Sanofi have reported earnings, with most beating estimates and providing positive guidance for 2025.

As of Jan. 29, 12.3% of Medical sector companies have reported quarterly earnings, with 85.7% beating on earnings and 57.1% exceeding revenue expectations. Year-over-year, earnings and revenues have increased by 1.4% and 6.6%, respectively. Overall, fourth-quarter earnings and sales are expected to rise by 12.5% and 8.6%.

Five biotech companies – Amgen, CRISPR Therapeutics, Moderna, Sarepta Therapeutics, and Vertex Pharmaceuticals – are projected to outperform in their upcoming quarterly results. Using the Earnings ESP method, these companies have a strong chance of delivering an earnings surprise. The Zacks Stock Screener can help identify these promising stocks.

Amgen, a leading biotech company, is expected to report fourth-quarter earnings of $5.03 per share. With a history of beating earnings estimates, Amgen is scheduled to release its earnings on Feb. 4 after the market closes. The company has an Earnings ESP of +1.74% and a Zacks Rank #3.

CRISPR Therapeutics, focusing on gene-editing therapeutics, is projected to report a loss of $1.17 per share in the fourth quarter. With an Earnings ESP of +2.49% and a Zacks Rank #3, the company has a track record of beating earnings estimates. Moderna, a biotech company specializing in mRNA-based therapies, is expected to report a loss of $2.86 per share for the fourth quarter. With an Earnings ESP of +8.41% and a Zacks Rank #3, Moderna has consistently beaten earnings estimates.

Sarepta Therapeutics, a biopharmaceutical company targeting rare diseases, is expected to report earnings of $1.69 per share in the fourth quarter. With an Earnings ESP of +18.55% and a Zacks Rank #2, Sarepta has a strong history of beating earnings estimates. Vertex Pharmaceuticals, focusing on small molecule drugs for serious diseases, is expected to report earnings of $4.00 per share in the fourth quarter. With an Earnings ESP of +1.63% and a Zacks Rank #3, Vertex has a positive track record of beating earnings estimates.



Read more at Nasdaq:: Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?